Cancer risk in hyperprolactinemia patients: A population-based cohort study

European Journal of Endocrinology

Volumn 165, Issue 2, 2011, Pages 209-215

  Berinder, Katarina ^a   Akre, Olof ^a   Granathand, Fredrik ^a   Hulting, Anna Lena ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERPROLACTINEMIA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK REDUCTION; SWEDEN; UTERINE CERVIX CANCER; UTERUS CANCER; CASE CONTROL STUDY; FOLLOW UP; HYPOPHYSIS TUMOR; MIDDLE AGED; NEOPLASM; POPULATION; PROLACTINOMA; REGISTER; RISK FACTOR; MALIGNANT NEOPLASTIC DISEASE; UPPER GASTROINTESTINAL TRACT;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPROLACTINEMIA; MALE; MIDDLE AGED; NEOPLASMS; PITUITARY NEOPLASMS; POPULATION; PROLACTINOMA; REGISTRIES; RISK FACTORS; YOUNG ADULT;

EID: 79960163503     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0076     Document Type: Article

References (44)

1. Ben-Jonathan N, Mershon JL, Allen DL & Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocrine Reviews 1996 17 639-669. (doi:10.1210/edrv-17-6-639)
2. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA & Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. Journal of Clinical Endocrinology and Metabolism 2006 91 4769-4775. (doi:10.1210/jc.2006-1668)
3. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA & Giustina A. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clinical Endocrinology 2006 65 265-273. (doi:10.1111/j.1365-2265. 2006.02562.x)
4. Delgrange E, Trouillas J, Maiter D, Donckier J & Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. Journal of Clinical Endocrinology and Metabolism 1997 82 2102-2107. (doi:10.1210/jc.82.7.2102)
5. Liby K, Neltner B, Mohamet L, Menchen L & Ben-Jonathan N. Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth. Breast Cancer Research and Treatment 2003 79 241-252. (doi:10.1023/A: 1023956223037)
6. Welsch CW, Louks G, Fox D & Brooks C. Enhancement by prolactin of carcinogen induced mammary cancerigenesis in the male rat. British Journal of Cancer 1975 32 427-431. (doi:10.1038/bjc.1975.243)
7. Strungs I, Gray RA, Rigby HB & Strutton G. Two case reports of breast carcinoma associated with prolactinoma. Pathology 1997 29 320-323. (doi:10.1080/00313029700169205)
8. Haga S, Watanabe O, Shimizu T, Iida T, Imamura H, Kajiwara T & Fujibayashi M. Breast cancer in a male patient with prolactinoma. Surgery Today 1993 23 251-255. (doi:10.1007/BF00309236)
9. Forloni F, Giovilli M, Pecis C, Bortolani E, Preziosi A, Barzaghi ME, Corti D & Beck-Peccoz P. Pituitary prolactin-secreting macroadenoma combined with bilateral breast cancer in a 45-year-old male. Journal of Endocrinological Investigation 2001 24 454-459Pubitemid 32573797)
10. Tworoger SS, Eliassen AH, Rosner B, Sluss P & Hankinson SE. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Research 2004 64 6814-6819. (doi:10.1158/0008-5472.CAN-04-1870)
11. Tworoger SS, Eliassen AH, Sluss P & Hankinson SE. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. Journal of Clinical Oncology 2007 25 1482-1488. (doi:10.1200/JCO.2006.07.6356)
12. Dekkers OM, Romijn JA, de Boer A & Vandenbroucke JP. The risk for breast cancer is not evidently increased in women with hyperprolactinemia. Pituitary 2010 13 195-198. (doi:10.1007/s11102-009-0214-y)
13. Crepin A, Bidaux G, Vanden-Abeele F, Dewailly E, Goffin V, Prevarskaya N & Slomianny C. Prolactin stimulates prostate cell proliferation by increasing endoplasmic reticulum content due to SERCA 2b over-expression. Biochemical Journal 2007 401 49-55. (doi:10.1042/BJ20060870)
14. Negro-Vilar A, Saad WA & McCann SM. Evidence for a role of prolactin in prostate and seminal vesicle growth in immature male rats. Endocrinology 1977 100 729-737. (doi:10.1210/endo-100-3-729)
15. Hsing AW & Comstock GW. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiology, Biomarkers and Prevention 1993 2 27-32.
16. Stattin P, Rinaldi S, Stenman UH, Riboli E, Hallmans G, Bergh A & Kaaks R. Plasma prolactin and prostate cancer risk: a prospective study. International Journal of Cancer 2001 92 463-465. (doi:10.1002/ijc.1191)
17. Levina VV, Nolen B, Su Y, Godwin AK, Fishman D, Liu J, Mor G, Maxwell LG, Herberman RB, Szczepanski MJ, Szajnik ME, Gorelik E & Lokshin AE. Biological significance of prolactin in gynecologic cancers. Cancer Research 2009 69 5226-5233. (doi:10.1158/0008-5472.CAN-08-4652)
18. Bhatavdekar JM, Patel DD, Chikhlikar PR, Shah NG, Vora HH, Ghosh N & Trivedi TI. Ectopic production of prolactin by colorectal adenocarcinoma. Diseases of the Colon and Rectum 2001 44 119-127. (doi:10.1007/BF02234833)
19. Bhatavdekar JM, Patel DD, Vora HH, Shah NG, Chikhlikar PR & Ghosh N. Prolactin as a local growth promoter in patients with locally advanced tongue cancer: GCRI experience. Head and Neck 2000 22 257-264. (doi:10.1002/(SICI)1097- 0347(200005)22:3〈257::AID-HED8〉3.0.CO;2-K)
20. Hatfill SJ, Kirby R, Hanley M, Rybicki E & Bohm L. Hyperprolactinemia in acute myeloid leukemia and indication of ectopic expression of human prolactin in blast cells of a patient of subtype M4. Leukemia Research 1990 14 57-62. (doi:10.1016/0145-2126(90)90146-Z)
21. Gado K, Rimanoczi E, Hasitz A, Gigler G, Toth BE, Nagy GM, Paloczi K & Domjan G. Elevated levels of serum prolactin in patients with advanced multiple myeloma. Neuroimmunomodulation 2001 9 231-236. (doi:10.1159/000049031)
22. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU & Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. European Journal of Epidemiology 2009 24 659-667. (doi:10.1007/s10654-009-9350-y)
23. Barlow L, Westergren K, Holmberg L & Talback M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncologica 2009 48 27-33. (doi:10.1080/02841860802247664)
24. Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M, Obradovic S, Zoric S, Simic M, Penezic Z & Marinkovic J. Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clinical Endocrinology 1998 49 441-445. (doi:10.1046/j.1365-2265.1998.00536.x)
25. Jenkins PJ. Cancers associated with acromegaly. Neuroendocrinology 2006 83 218-223. (doi:10.1159/000095531)
26. Franks S, Jacobs HS & Nabarro JD. Prolactin concentrations in patients with acromegaly: clinical significance and response to surgery. Clinical Endocrinology 1976 5 63-69. (doi:10.1111/j.1365-2265.1976.tb03804.x)
27. Goffin V, Bernichtein S, Touraine P & Kelly PA. Development and potential clinical uses of human prolactin receptor antagonists. Endocrine Reviews 2005 26 400-422. (doi:10.1210/er.2004-0016)
28. Veronesi U, Boyle P, Goldhirsch A, Orecchia R & Viale G. Breast cancer. Lancet 2005 365 1727-1741. (doi:10.1016/S0140-6736(05)66546-4)
29. Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM & Harkonen PL. Prolactin and prolactin receptors are expressed and functioning in human prostate. Journal of Clinical Investigation 1997 99 618-627. (doi:10.1172/JCI119204)
30. Wennbo H, Kindblom J, Isaksson OG & Tornell J. Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology 1997 138 4410-4415. (doi:10.1210/en.138.10.4410)
31. Colao A, Vitale G, Di Sarno A, Spiezia S, Guerra E, Ciccarelli A & Lombardi G. Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma. Journal of Clinical Endocrinology and Metabolism 2004 89 2770-2775. (doi:10.1210/jc.2003-032055)
32. Bouchard P, Lagoguey M, Brailly S & Schaison G. Gonadotropin- releasing hormone pulsatile administration restores luteinizing hormone pulsatility and normal testosterone levels in males with hyperprolactinemia. Journal of Clinical Endocrinology and Metabolism 1985 60 258-262. (doi:10.1210/jcem-60-2-258)
33. Gann PH, Hennekens CH, Ma J, Longcope C & Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. Journal of the National Cancer Institute 1996 88 1118-1126. (doi:10.1093/jnci/88.16.1118)
34. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ & Auvinen A. Screening and prostate-cancer mortality in a randomized European study. New England Journal of Medicine 2009 360 1320-1328. (doi:10.1056/NEJMoa0810084)
35. Rosenquist K, Wennerberg J, Schildt EB, Bladstrom A, Hansson BG & Andersson G. Use of Swedish moist snuff, smoking and alcohol consumption in the aetiology of oral and oropharyngeal squamous cell carcinoma. A population-based case-control study in Southern Sweden. Acta Otolaryngologica 2005 125 991-998. (doi:10.1080/00016480510043440)
36. Bole-Feysot C, Goffin V, Edery M, Binart N & Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocrine Reviews 1998 19 225-268. (doi:10.1210/er.19.3.225)
37. Montgomery DW. Prolactin production by immune cells. Lupus 2001 10 665-675. (doi:10.1191/096120301717164895)
38. Clevenger CV, Altmann SW & Prystowsky MB. Requirement of nuclear prolactin for interleukin-2 - stimulated proliferation of T lymphocytes. Science 1991 253 77-79. (doi:10.1126/science.2063207)
39. Al-Sakkaf KA, Mooney LM, Dobson PR & Brown BL. Possible role for protein kinase B in the anti-apoptotic effect of prolactin in rat Nb2 lymphoma cells. Journal of Endocrinology 2000 167 85-92. (doi:10.1677/joe.0.1670085)
40. DiMattia GE, Gellersen B, Bohnet HG & Friesen HG. A human B-lymphoblastoid cell line produces prolactin. Endocrinology 1988 122 2508-2517. (doi:10.1210/endo-122-6-2508)
41. Matera L, Geuna M, Pastore C, Buttiglieri S, Gaidano G, Savarino A, Marengo S & Vonderhaar BK. Expression of prolactin and prolactin receptors by non-Hodgkin's lymphoma cells. International Journal of Cancer 2000 85 124-130. (doi:10.1002/(SICI)1097-0215(20000101)85:1〈124::AID-IJC22〉3. 0.CO;2-U)
42. Wang PS, Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levin R & Avorn J. Dopamine antagonists and the development of breast cancer. Archives of General Psychiatry 2002 59 1147-1154. (doi:10.1001/archpsyc.59.12.1147)
43. Dalton SO, Johansen C, Poulsen AH, Norgaard M, Sorensen HT, McLaughlin JK, Mortensen PB & Friis S. Cancer risk among users of neuroleptic medication: a population-based cohort study. British Journal of Cancer 2006 95 934-939. (doi:10.1038/sj.bjc.6603259)
44. Bajaj A, Driver JA & Schernhammer ES. Parkinson's disease and cancer risk: a systematic reviewandmeta-analysis. Cancer Causes and Control 2010 21 697-707. (doi:10.1007/s10552-009-9497-6)